Clinical Trial Detail

NCT ID NCT01834651
Title A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors Edwin Posadas, MD
Indications

prostate cancer

Therapies

Cabozantinib

Age Groups: adult

No variant requirements are available.